CustomerValidation
- •NatMed.2014Aug;20(8):927-35.
- •NatImmunol.2017Oct2.
- •Gastroenterology.2015Feb;148(2):392-402.e13.
- •NucleicAcidsRes.2017May5;45(8):4743-4755.
- •EMBORep.2016Jul;17(7):1013-28.
- •PLoSPathog.2017Jun8;13(6):e1006343.
- •PLoSPathog.2017May11;13(5):e1006374.
- •PLoSPathog.2015Mar30;11(3):e1004758.
- •JMedChem.2016Nov23;59(22):10268-10284.
- •BrJPharmacol.2015Jun23.
- •BrJPharmacol.2014Jan;171(1):237-52.
- •IntJRADIatOncolBiolPhys.2016Nov15;96(4):867-876.
- •Nanomedicine.2017Jan;13(1):49-58.
- •JVirol.2014May;88(10):5578-94.
- •FrontPharmacol.2016Dec21;7:490.
- •IntJAntimicrobAgents.2015Oct;46(4):381-8.
- •AntimicrobAgentsChemother.2015May;59(5):2496-507.
- •AntimicrobAgentsChemother.2014Aug;58(8):4555-64.
- •AntimicrobAgentsChemother.2014Jun;58(6):3327-34.
- •AntimicrobAgentsChemother.2013Mar;57(3):1180-91.
- •AntiviralRes.2017Oct23;148:5-14.
- •AntiviralRes.2017Oct;146:191-200.
- •AntiviralRes.2017Mar;139:18-24.
- •AntiviralRes.2016Aug;132:287-95.
- •AntiviralRes.2013Jul;99(1):6-11.
- •SciRep.2016Oct5;6:34652.
- •FrontMicrobiol.2017Jun19;8:1129.
- •PLoSOne.2016Jul21;11(7):e0159511.
- •PLoSOne.2016Jun9;11(6):e0156996.
- •PLoSOne.2016Apr22;11(4):e0152036.
- •PLoSOne.2016Mar29;11(3):e0152236.
- •VirusRes.2017Mar18;235:37-48.
- •HepatolRes.2017Aug19.
- •BiomedResInt.2017;2017:1236801.
- •ChemBiolDrugDes.2017Aug21.
- •NatProdRes.2017Feb;31(3):341-346.
- •TransplInfectDis.2017Nov7.
- •JVirolMethods.2015Jun15;218:59-65.
- •HepatolCommun.2017;1(6).
- •HepatolCommun.June6,2017.
- •UniversidadAutónomadeMadrid.2016-01-12.
- •OpenVirolJ.2014Mar7;8:1-8.
Description | PSI-7977isanactiveinhibitorofHCVRNAreplicationintheHCVrepliconassay,demonstratespotentanti-hepatitisCvirus(HCV)activity. |
---|---|
IC50&Target | EC50:92±5nM(HCV)[1] |
InVitro | WhencathepsinA(CatA)isincubatedwithPSI-7977orPSI-7976for150min,~18-foldmorePSI-352707isformedwhenPSI-7977isthesubstratecomparedwithPSI-7976.Moreover,thecatalyticefficiencyforPSI-7977withCatAis~30-foldhigherthanthatforPSI-7976[1].ThegenotypecoverageofPSI-7977byusingGT1b(Con1)-,1a(H77)-,and2a(JFH-1)-derivedrepliconsandGT1bchimericrepliconscontainingtheNS5BregionfromtheJ6GT2aisolateandfromGT2bandGT3apatientisolatesisevaluated,PSI-7977inhibitsthereplicationoftheserepliconswithsimilarEC50s(between16and48nM),andisespeciallyactiveagainstthechimericrepliconcontainingtheJ6NS5B(EC50=4.7nM).PSI-7977inhibitscloneA(GT1b)wild-typeandS282TrepliconswithEC90valuesof0.42and7.8μM,respectively[2].InthecloneArepliconassay,PSI-7977producesanti-HCVactivitywithEC90values0.42μM[3]. |
ClinicalTrial | ViewMoreCollapse |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellAssay [1] | PSI-7977isdissolvedinDMSOandstored,andthendilutedwithappropriatemediumbeforeuse[1]. CloneAcellsareseededintoT75flasksatabout5×106cells/flaskinDulbecco"smodifiedEagle"smedium(DMEM)containing100IU/mLPenicillin/100μg/mLstreptomycinand10%fetalbovineserum.Similarly,humanprimaryhepatocytesareseededincellplatingmediumintoT75flasksatabout5×106cells/flask.Afterovernightincubationtoallowthecellstoattach,cellsareincubatedwith50μMPSI-7851,PSI-7976,orPSI-7977infreshmediumforcloneAcellsorincellmaintenancemediumforprimaryhepatocytesforupto24hat37°Cina5%CO2atmosphere.ThesameproceduresareappliedwhenradiolabeledPSI-7851isusedinthestudyexceptthat1×106cellsperwellareseededintoa6-wellplate,andthecellsareincubatedwith5μM[3H]PSI-7851.Atselectedtimes,themediumisremoved,andthecelllayeriswashedwithcoldphosphate-bufferedsaline(PBS).Aftertrypsinization,cellsarecountedandcentrifugedat1,200rpmfor5min.ThecellpelletsaresUSPendedin1mLofcold60%methanolandincubatedovernightat−20°C.Thesamplesarecentrifugedat14,000rpmfor5min,andthesupernatantsarecollectedanddriedusingaSpeedVacconcentratorandstoredat−20°Cuntiltheyareanalyzedbyhighperformanceliquidchromatography(HPLC).Residuesaresuspendedin100μLofwater,and50-μLaliquotsareinjectedintoHPLC[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
References |
|
MolecularWeight | 529.45 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₂₂H₂₉FN₃O₉P | ||||||||||||
CASNo. | 1190307-88-0 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | 10mMinDMSO *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> Purity:99.95% 品牌介绍
托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH,5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50~89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者,应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射,并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似,均可达81%~100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用,可加快代谢,故快代谢型者需增加剂量,慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶,熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride):C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应,可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品
联络我们
|